Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in Stage IIIA-N2 Non-small Cell Lung Cancer

Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in... EDITORIAL Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in Stage IIIA-N2 Non-small Cell Lung Cancer Johan Vansteenkiste, MD, PhD,* Daniel Betticher, MD, PhD,† Wilfried Eberhardt, MD,‡ and Paul De Leyn, MD, PhD§ recent article in the Journal of the National Cancer Institute presented results of the AEORTC 08941 study. The main conclusion was that surgical (i.e., chemotherapy and surgical resection) and non-surgical multimodality treatments (chemotherapy and radio- therapy) led to similar 5-year survival rates of approximately 15% among selected patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with response to induction chemotherapy. This important study must be understood in its appropriate context of patients with unresectable IIIA-N2 disease: induction chemotherapy did not convert unresectable disease into resectable—as illustrated by the 50% incomplete resection rate in the surgery arm—and, not unexpectedly, did not result in better outcome compared with radiotherapy. The crucial term “unresectable” was not clearly defined in the article. In the initial protocol (October 15, 1994), patients were eligible if “judged by the responsible surgeon to have irresectable N2-disease.” This vital criterion was amended to the “guidelines for irresectability” as they are mentioned in the publication on page 443, by an amendment on September http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in Stage IIIA-N2 Non-small Cell Lung Cancer

Journal of Thoracic Oncology , Volume 2 (8) – Aug 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/randomized-controlled-trial-of-resection-versus-radiotherapy-after-zN20ARloce

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31811f47ad
pmid
17762333
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in Stage IIIA-N2 Non-small Cell Lung Cancer Johan Vansteenkiste, MD, PhD,* Daniel Betticher, MD, PhD,† Wilfried Eberhardt, MD,‡ and Paul De Leyn, MD, PhD§ recent article in the Journal of the National Cancer Institute presented results of the AEORTC 08941 study. The main conclusion was that surgical (i.e., chemotherapy and surgical resection) and non-surgical multimodality treatments (chemotherapy and radio- therapy) led to similar 5-year survival rates of approximately 15% among selected patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with response to induction chemotherapy. This important study must be understood in its appropriate context of patients with unresectable IIIA-N2 disease: induction chemotherapy did not convert unresectable disease into resectable—as illustrated by the 50% incomplete resection rate in the surgery arm—and, not unexpectedly, did not result in better outcome compared with radiotherapy. The crucial term “unresectable” was not clearly defined in the article. In the initial protocol (October 15, 1994), patients were eligible if “judged by the responsible surgeon to have irresectable N2-disease.” This vital criterion was amended to the “guidelines for irresectability” as they are mentioned in the publication on page 443, by an amendment on September

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Aug 1, 2007

References